Gleevec

Small Doses: The Weekly News You Need to Know
Small Doses: The Weekly News You Need to KnowSmall doses is a weekly slideshow of the news you may have missed, made just for you and your busy lifestyle.
Express Scripts’ 2016 Drug Trend Report: 7 things to knowReport highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.
Medicare drug pricing debate heats upA senator is investigating whether Medicare's prescription drug benefit is vulnerable to manipulation by pharmaceutical companies after an exclusive Associated Press report showed that Medicare’s spending on certain drugs soared by 85 percent.
Generic treatment for chronic myeloid leukemia could save millionsFive years of imatinib treatment for CML = >$100,000 saved per patient.
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
Watch list 2016: Top therapeutic areas
Watch list 2016: Top therapeutic areasExperts say you should follow these 6 therapeutic areas.
ASH: 6-year data reinforce superiority of nilotinib over imatinib in newly-diagnosed patients with Ph+ CMLNilotinib (Tasigna) should be considered as a leading option for front-line therapy in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), according to data presented at the 56th ASH Annual Meeting and Exposition in San Francisco.
Patient access to orphan drugs faces new set of challengesIn 1983, the United States enacted the Orphan Drug Act (ODA). An analogous law was passed in Europe in 2000. Both pieces of legislation are considered major successes in terms of spurring the development of orphan drugs. To illustrate, in the decade prior to 1983 only 34 orphan products were marketed, whereas in the past year alone 9 orphan drugs were launched. In the past 5 years, 39 orphan drugs were launched in the US across numerous therapeutic categories, including multiple myeloma, chronic myeloid leukemia, metastatic non-small cell lung cancer, hemophilia, tuberculosis, homozygous familial hypercholesterolemia, and cystic fibrosis.1
Four-year update shows nilotinib induces significantly deeper molecular responses than imatinibThe 4-year data from the landmark ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials – Newly Diagnosed Patients) trial continues to demonstrate the improved clinical benefit of front-line nilotinib (Tasigna) versus imatinib (Gleevec) in patients with newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase